A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Clinical trial NCT07188896 · RECRUITING

Trial details

NCT number: NCT07188896
Sponsor: Brian Rini
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Renal Cell Carcinoma (aRCC)Metastatic Renal Cell Carcinoma ( mRCC)Clear Cell Renal Cell Carcinoma (ccRCC)

Start date: 2026-04-29
Primary completion: 2029-11-30
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.